Lymphoma Cancer | Tumor

Immunotherapy Options Around the Bend

June 18th 2021, 1:00pm


One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

Yescarta Associated With Better Outcomes Than Other Available Treatments for Relapsed/Refractory Follicular Lymphoma

June 14th 2021, 6:00pm


These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.

Learning to Live with an Incurable, Inoperable Cancer

June 10th 2021, 3:00pm


In this episode of the “CURE® Talks Cancer” podcast, author Steve Kelley shares both the painful and positive moments of his journey with a rare cancer.

Novel Triplet Combination Shows ‘Notable Efficacy in a Challenging to Treat’ Population of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

June 6th 2021, 2:00pm


Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.

Aliqopa Plus Rituximab Improves Survival for Relapsed Non-Hodgkin Lymphoma

June 3rd 2021, 9:00pm


Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.

CURE’s Clinical Trial Corner: May 2021

May 27th 2021, 9:00pm


As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

Adcetris Plus Combo Chemotherapy May Impact Survival and Response to Treatment in Subset of Patients With Hodgkin Lymphoma

May 27th 2021, 1:00pm


For patients with early-stage, unfavorable-risk Hodgkin lymphoma, this treatment option may allow for the reduction or elimination of radiotherapy in patients without malignant disease.

FDA Approves Zynlonta for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

April 23rd 2021, 7:16pm


The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Friday Frontline: A 22-Year-Old Cancer Survivor Prepares to Bike Across the Country, Actress Helen McCrory Dies From Cancer, And More

April 23rd 2021, 3:00pm


From a college student who survived lymphoma biking 4,000 miles for charity to the death of “Harry Potter” actress Helen McCrory, here’s what’s happening in the cancer landscape this week.

Keytruda Improves Progression-Free Survival in Subset of Patients With Relapsed/Refractory Hodgkin Lymphoma

April 19th 2021, 9:00pm


Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.